May 2 - In a bold move, Danco Laboratories and GenBioPro have thrown down the gauntlet, asking the U.S. Supreme Court to reinstate mail-order access to mifepristone, a crucial medication for abortion. This request comes hot on the heels of an appeals court's decision that has thrown a wrench into the delivery of this widely used drug, particularly in states where abortion is already under siege.
Just one day after the appeals court's ruling, which has temporarily halted deliveries, these pharmaceutical titans filed their applications with the highest court. The lower court's decision marks a significant blow to access, igniting a firestorm of legal battles surrounding mifepristone's approval and its availability since 2000.
This latest skirmish is part of a larger war over reproductive rights that escalated after the Supreme Court's 2022 decision to overturn Roe v. Wade, dismantling the constitutional protections for abortion. With nearly half of U.S. states now imposing severe restrictions or outright bans on abortion, the demand for medication abortions has surged, leading to a flurry of legal confrontations over access to these pills.
Danco expressed its frustration, stating that Friday’s ruling “injects immediate confusion and upheaval into highly time-sensitive medical decisions,” leaving everyone from patients to pharmacies in a state of uncertainty about what is permissible. Meanwhile, GenBioPro asserted its commitment to ensuring that everyone has access to safe and affordable healthcare.
Mifepristone is a key player in about two-thirds of U.S. abortions, typically used in conjunction with misoprostol to terminate pregnancies within the first ten weeks. In a significant policy shift in 2023, the FDA under President Biden lifted previous restrictions requiring in-person prescriptions for mifepristone, citing its safety and efficacy.
However, a conservative panel from the 5th U.S. Circuit Court of Appeals recently ruled that Louisiana is likely to win its challenge against the FDA’s regulations. Louisiana's lawsuit claims that the FDA has overlooked serious risks associated with mifepristone, such as sepsis and hemorrhaging.
For Republican-led states like Louisiana, restricting access to mifepristone—especially through telehealth services with out-of-state providers—has become a top priority since the abortion bans were enacted. The Trump administration had previously indicated it was reviewing mifepristone’s safety, but reports suggest that this review has been stalled until after the upcoming midterm elections.
Earlier this month, a U.S. district judge had put Louisiana’s lawsuit on hold while awaiting the administration’s findings. GenBioPro voiced concerns that anti-abortion advocates are trying to undermine the FDA’s authority over drug regulation.
Legal experts are sounding alarms about the implications of these developments. Skye Perryman, President and CEO of Democracy Forward, stated, “Our nation is once again facing a generational-defining moment for women’s healthcare.” She emphasized that the fight for women’s health didn’t end with the Dobbs decision.
Both Danco and GenBioPro have intervened in Louisiana’s lawsuit to defend the FDA's regulations. Mifeprex is Danco’s sole product, while GenBioPro primarily profits from its generic version. Another player in this arena is Evita Solutions, which also produces a generic variant.
In 2024, the Supreme Court will hear a separate challenge regarding mail-order access brought forth by medical groups and doctors; however, they were deemed to lack legal standing to pursue the case. States like Missouri, Kansas, and Idaho have since taken over this contentious issue, which remains unresolved.
